Synlogic
SYBXPhase 3Synlogic develops synthetic biotic medicines engineered to treat metabolic and immunological diseases by leveraging the microbiome.
Market Cap
$8.4M
Founded
2013
Focus
Biotech
About
Synlogic develops synthetic biotic medicines engineered to treat metabolic and immunological diseases by leveraging the microbiome.
Pipeline Snapshot
1010 drugs in pipeline, 1 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| SYNB1934v1 + Placebo | Phenylketonuria | Phase 3 |
| SYNB1618 + SYNB1934 | Phenylketonuria | Phase 2 |
| SYNB1618 + Placebo | Phenylketonuria | Phase 1/2 |
| SYNB1020 | Cirrhosis | Phase 1/2 |
| SYNB8802v1 | Enteric Hyperoxaluria | Phase 1 |
Funding History
3Total raised: $140M
IPO$70MUndisclosedSep 28, 2017
Series B$40MUndisclosedJun 15, 2016
Series A$30MAtlas VentureJun 15, 2014
Company Info
TypePublic
Founded2013
LocationCambridge, United States
StagePhase 3
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile